Palladyne AI Corp. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. Palladyne, formerly Sarcos Technology and Robotics Corporation, changed its name in March as it shifted from hardware development to an AI/ML robotics software strategy.
Financial performance and liquidity
| Metric | Q1 2024 | Q1 2023 |
|---|---|---|
| Revenue | $3.441 million | $2.296 million |
| Gross profit and gross margin | Approximately $1.555 million; 45% | Approximately $0.510 million; 22% |
| Operating expenses | $10.794 million | $25.484 million |
| Operating loss | $(7.353) million | $(23.188) million |
| Net loss | $(7.229) million; $(0.28) per share | $(21.476) million; $(0.84) per share |
| Cash used in operations | $(7.236) million | $(20.122) million |
Revenue comprised $2.559 million of legacy product sales and $0.882 million of product-development contracts. The filing reports no commercial customers for the AI/ML Software Platform. Gross profit and margins above are calculated from reported revenue and cost of revenue.
At March 31, cash and cash equivalents were $31.798 million, with no marketable securities reported on the balance sheet; the filing notes that approximately $15.0 million of Treasury securities were held as cash equivalents. Working capital was $30.3 million. Total liabilities were $16.2 million, including $12.1 million of operating lease liabilities; the filing reports no borrowings. Management believes available resources are sufficient for at least 12 months from the report date, while noting that additional financing could be sought.
Changes versus prior-year quarter
- Revenue rose 50%, as $2.559 million of legacy product sales more than offset a 62% decline in development-contract revenue, primarily following completion of contracts during 2023.
- Operating expenses fell 58%, largely reflecting workforce reductions in 2023. Research and development declined 69%, general and administrative 47%, and sales and marketing 78%.
- Net loss narrowed by $14.247 million. Lower operating costs drove the improvement; other income also fell, in part because Q1 2023 included employee retention credit refunds and higher interest income.
- Operating cash use declined by $12.886 million. Cash increased $8.659 million during the quarter, supported by $16.0 million of marketable-security maturities.
Outlook, management commentary, and risks
- Management expected the platform to be ready for initial customer testing in June 2024, initial customer trials during the second half of 2024, and commercial-customer revenue in 2025. These are forward-looking targets, not assured outcomes.
- Backlog was $4.2 million ($2.8 million funded and $1.4 million unfunded); most was expected to be recognized within 12 months. Total estimated contract value, including potential value from unexercised options, was $14.1 million.
- The company has suspended development and commercialization of hardware products and is prioritizing software. It says development timing, customer adoption, pricing, sales cycles, and future software revenue remain uncertain; it has no prior commercial software licensing track record.
- Key risks include continued losses and negative operating cash flow, possible need for new capital, product-development or customer-trial delays, competition, AI and data-security regulation, software defects and safety or liability claims, supplier dependence, and loss of key personnel. Recent workforce reductions may also constrain execution.
- On April 17, 2024, after quarter-end, the company repriced options covering 753,551 shares to $1.59 per share; options for 225,670 shares held by seven senior employees also had their vesting schedule restarted. The company reported no material legal-loss contingency and no material legal proceedings it believed would adversely affect it.
- Management concluded disclosure controls were effective as of March 31, 2024, and reported no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Whether platform development, June testing, second-half trials, and the targeted 2025 commercial revenue timeline are achieved.
- How much of the reported backlog is funded, converted to revenue, and replaced as legacy development contracts conclude.
- Cash burn, available liquidity, and financing needs if commercialization is delayed; management’s 12-month liquidity assessment is an estimate.
- Customer evidence of platform performance, willingness to pay, adoption, and recurring-license economics.
- Potential dilution: 20.55 million warrants were outstanding at quarter-end, and up to 4.69 million earn-out shares may be issuable if specified stock-price targets are met.